Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Case Comprehensive Cancer Center
Study ID
NCT06455189
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Control Group - Standard of care neurosurgical resection — OTHER
    The control group will include only standard of care tools. - Standard of care neurosurgical resection will include the use of all standard neurosurgical instruments and techniques (eg, microscope, intraoperative ultrasound, 5-ALA fluorescence guided surgery and neuronavigation system).
  • MRF/MRI infiltration guidance for extended resection — PROCEDURE
    Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body

Study Details

Magnetic resonance imaging, MRI, is a procedure that uses radio waves, a powerful magnet, and a computer to make a series of detailed pictures of areas inside the body. The goal of this study is to determine if MR fingerprinting, new way of acquiring MRI images, can help identify the extent of tumor spread in the brain, better than routine MRI images.

Key Dates

Start date
Dec 31, 2025
Status verified
Aug 2025
Primary completion
Jun 1, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
114 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Other: Group 1
    Routine standard of care process will be followed for neurosurgical guidance
  • Experimental: Group 2
    The surgeon will have access to advanced MRI and MRF analysis research images during surgery and may use them for guidance, in addition to all routinely used surgical tools.

Primary Outcome Measure

Number of participants who experienced serious adverse events(SAEs) at 48 hours post targeted biopsy sampling procedure [ Time Frame: 48 hours post surgery ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University Hospitals Cleveland Medical Center, UH Department of Radiology, Case Comprehensive Cancer CenterClevelandOhio44106
Chaitra Badve, MD
[email protected]
216-844-3312

Find similar trials in Cleveland, OH

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
University Hospitals Cleveland Medical Center, UH Department of Radiology, Case Comprehensive Cancer Center· Cleveland, OH

Related Studies